Agios Pharmaceuticals Inc (NASDAQ:AGIO) Reports Mixed Q2 2025 Results: Revenue Beat but Wider EPS Loss

Agios Pharmaceuticals Inc (NASDAQ:AGIO) reported its second-quarter 2025 financial results, delivering mixed performance relative to analyst expectations. The biopharmaceutical company, focused on rare disease therapies, posted revenue of $12.46 million, surpassing the consensus estimate of $9.67 million. However, its earnings per share (EPS) of -$1.93 fell short of the projected -$1.84.

Key Financial Highlights

• Revenue Beat: The company’s Q2 revenue of $12.46 million exceeded expectations by approximately 29%, reflecting stronger-than-anticipated performance in its commercial and development-stage programs.
• EPS Miss: Despite the revenue beat, Agios reported a wider-than-expected loss per share at -$1.93, compared to the estimated -$1.84. This suggests higher operational costs or R&D expenditures.
• Market Reaction: In pre-market trading, AGIO shares declined by ~10.66%, indicating investor disappointment, likely driven by the deeper EPS loss despite the revenue outperformance.

Business and Pipeline Updates

The press release highlighted progress across Agios’ rare disease portfolio:

• PYRUKYND (mitapivat): The company continues to advance its lead PK activator for hemolytic anemias, with ongoing clinical trials and regulatory discussions.
• Tebapivat: Development continues for lower-risk myelodysplastic syndromes (LR MDS) and other hemolytic anemias.
• AG-181 (PAH stabilizer): Progress in phenylketonuria (PKU) research, though no major milestones were disclosed.
• AG-236 (siRNA therapy): Early-stage development for polycythemia vera (PV) in collaboration with Alnylam Pharmaceuticals.

Forward-Looking Estimates

Analysts project full-year 2025 revenue at $44.64 million, with an estimated EPS of -$7.38. For Q3, expectations stand at $10.14 million in revenue and an EPS of -$1.96. The company did not provide explicit guidance in its release, leaving investors to rely on external estimates.

Market Sentiment

The stock’s recent performance has been volatile:

• Last Week: -7.45%
• Last Two Weeks: -6.13%
• Last Month: +9.22%
  The post-earnings dip suggests that while revenue growth is encouraging, concerns over profitability and cash burn remain.

For a deeper dive into Agios’ earnings trends and analyst projections, see AGIO Earnings & Estimates.

Disclaimer: This article is for informational purposes only and does not constitute investment advice.